Angelman syndrome

Angelman syndrome is a neurodevelopmental condition caused by deficient expression or function of the maternally inherited UBE3A allele in the brain. Development, movement, communication, sleep, feeding, and seizure risk may be affected. Features and support needs vary by person and by molecular mechanism.1

Urgent safety

Follow the person's seizure action plan. Call emergency services for a seizure that reaches the plan's emergency threshold, repeated seizures without recovery, breathing difficulty or color change, serious injury, or a first or substantially changed seizure. Some nonepileptic movements can resemble seizures, and EEG differences can persist when seizures are controlled, so treatment changes require specialist review.1

Seek urgent assessment for choking, inability to clear secretions, marked dehydration, acute loss of alertness or skills, or a fall with possible head or neck injury. Sudden change should not automatically be attributed to Angelman syndrome.

Clinical pattern and diagnosis

Possible features include:

• developmental and learning differences with speech that may be limited or absent;
• gait ataxia, tremulous movements, hypotonia in infancy, or later mobility limitations;
• seizures, characteristic but nonspecific EEG patterns, and sleep disturbance;
• feeding or swallowing difficulty, reflux, constipation, and growth concerns;
• strabismus, scoliosis, and other vision or orthopedic concerns;
• frequent smiling, laughter, excitability, or strong social interest in some people.

Laughter or smiling is not reliable evidence of comfort, agreement, or absence of pain. Behavior change may communicate pain, illness, fatigue, constipation, reflux, anxiety, a seizure change, or an inaccessible environment.

Diagnosis uses clinical findings and molecular testing. DNA methylation analysis can identify deletion, paternal uniparental disomy, or imprinting mechanisms but usually requires further testing to distinguish them. When methylation is normal and suspicion remains, UBE3A sequencing and deletion or duplication analysis may identify a pathogenic variant. A negative initial result does not exclude every Angelman-like condition, and a variant of uncertain significance is not diagnostic.1

Recurrence risk ranges from low to substantial depending on the molecular mechanism and parental findings. Genetic counseling should identify the mechanism before providing family-specific recurrence or reproductive guidance.1

Treatment and follow-up

There is no approved disease-modifying treatment. Care is directed to the person's seizures, sleep, gastrointestinal and nutrition needs, movement and orthopedic health, vision, dental care, learning, communication, and participation. Medication response and adverse effects vary; avoid oversedation and do not change antiseizure or sleep medicine without the treating clinician.1

Mobility equipment, positioning, exercise, behavioral support, school accommodations, and supervision should be selected from current function and goals. A diagnosis or genetic mechanism does not determine a specific device, teaching method, or level of independence.

Feeding and communication

Swallowing review should consider coughing or choking, respiratory symptoms, prolonged meals, fatigue, weight and hydration, reflux, constipation, positioning, and oral-motor function. Texture, pacing, posture, equipment, and exercises require direct assessment.1

Speech output often underrepresents what a person understands and intends. Treat body movement, facial expression, gaze, vocalization, gesture, sign, object use, and AAC as potential communication. Offer real choices, allow processing time, model language without demanding imitation, and confirm rather than guess. Communication support should expand autonomy, relationships, learning, and consent, not only request-making.

Use a multimodal system that may combine gestures or signs, objects, photos or symbols, writing, partner-assisted scanning, and speech-generating AAC. Do not assume that every person needs symbols, a touchscreen, a switch, or eye gaze. Trial access in meaningful activities while accounting for ataxia, tremor, vision, hearing, attention, seating, fatigue, and seizure state. Train partners, provide vocabulary beyond basic needs, include urgent messages and a reliable yes/no response, and keep a low-tech backup.2 For evaluation, trials, funding, and implementation, use the AAC device acquisition guide.

Coding

• ICD-10-CM Q93.51: Angelman syndrome.

Code associated epilepsy and other conditions only when documented and supported by current local coding rules.4

Sources

1. Dagli, Mathews, and Williams. Angelman Syndrome, GeneReviews — current diagnosis, molecular mechanisms, genetics, management, and surveillance (revised 2025).
2. Duis et al. Multidisciplinary consensus standards of care for Angelman syndrome — condition-specific seizure, sleep, gastrointestinal, orthopedic, developmental, and communication care (2022; PMID 35150089).
3. American Speech-Language-Hearing Association: Augmentative and Alternative Communication — individualized, multimodal AAC assessment without cognitive prerequisites.
4. Centers for Medicare & Medicaid Services: FY2026 ICD-10-CM definitions — Q93.51 descriptor.

Review boundary

This page cannot diagnose Angelman syndrome, interpret genetic results, or remotely assess seizures, swallowing, pain, nutrition, or safety. Emergencies require immediate local assessment. Rescue medication, other treatment, diet, equipment, mobility, communication, and genetic-counseling decisions require direct review by qualified clinicians with the person and family.